<DOC>
	<DOCNO>NCT02638896</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety etanercept dose reduction combine sulfasalazine ankylose spondylitis ( AS ) patient achieve significant clinical response .</brief_summary>
	<brief_title>Dose Reduction Etanercept Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description>This single-centre , open-labeled randomize study evaluate efficacy safety etanercept dose reduction combine sulfasalazine patient achieve significant clinical response . AS patient meet inclusion criterion take celecoxib ( 0.4g/d ) whole period study . In first period , patient give etanercept 50 mg subcutaneous injection weekly baseline week12 . In second period , patient satisfy criteria disease remission randomize one follow three treatment arm : ( 1 ) Dose reduction arm : Patients receive etanercept 50 mg subcutaneous injection every week plus sulfasalazine ( 2g/d ) oral administration till week24 . ( 2 ) Dose maintenance arm : Etanercept remain unchange week12 week24 . ( 3 ) Etanercept discontinuation arm : Patients treat sulfasalazine ( 2g/d ) oral administration till week24 . In third period , patient take sulfasalazine ( 2g/d ) till week 48 . Ankylosing spondylitis disease activity score ( ASDAS ) , erythrocyte sedimentation rate ( ESR ) , C-reactive protein ( CRP ) , Bath ankylose spondylitis functional index ( BASFI ) , Bath ankylose spondylitis metrology index ( BASMI ) , Spondyloarthritis research consortium Canada ( SPARCC ) score sacroiliac joint adverse effect assess study .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>1 . Patients 18 45 year age . 2 . Proven AS accord modify New York criteria 3 . Negative result pregnancy test serum screen visit urine baseline visit , do woman , except surgically sterilize least one year menopause . 4 . Sexually active woman childbearing potential must agree commit use medically accept form contraception . 5 . ASDAS score ≥2.1 6 . Ability reconstitute drug selfinject person . 7 . Capability understand voluntarily give write informed consent sign date , specific procedure protocol perform . 8 . Ability store injectable test article 2º 8º C. 1 . Pregnancy/lactation . 2 . Previously exposure murine chimeric monoclonal antibody . 3 . Receipt live ( attenuate ) vaccine within 4 week screen visit . 4 . History chronic recent serious infection . 5 . History tuberculosis within last 3 year . 6 . History malignancy . 7 . Significant concurrent medical disease include uncompensated congestive heart failure , myocardial infarction within 12 month , stable unstable angina pectoris , uncontrolled hypertension , severe pulmonary disease , history human immunodeficiency virus ( HIV ) infection , central nervous system demyelinate event suggestive multiple sclerosis . 8 . Presence history confirm blood dyscrasia . 9 . History viral hepatitis within 1 year prior screen history druginduced liver injury time prior screening . 10 . Laboratory exclusion : hemoglobin level &lt; 8.5 mg/dl white blood cell count &lt; 3.5×10e9/l , platelet count &lt; 125 ×10e9/l , creatinine level &gt; 175 mcmol/l , liver enzymes &gt; 1.5 time upper limit normal alkaline phosphatase &gt; 2 time upper limit normal . 11 . Participation trial investigational medication within 30 day enter study . 12 . Clinical examination show significant abnormality clinical relevance . 13 . Concomitant medication diseasemodifying antirheumatic drug ( DMARDs ) corticosteroid . 14 . Hypersensitivity regent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Sulfasalazine</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>dose</keyword>
	<keyword>reduction</keyword>
</DOC>